左西孟旦联合重组人脑利钠肽在急性心力衰竭中的应用
|
摘要
目的探讨左西孟旦联合重组人脑利钠肽治疗急性心力衰竭的临床治疗效果。方法将我院急诊内科收治的急性心力衰竭患者40例随机分为对照组与观察组,每组各20例。对照组给予左西孟旦治疗;观察组给予左西孟旦与重组人脑利钠肽联合治疗。选取治疗前及治疗72 h后作为观察时点,比较两组患者疗效与NT-proBNP水平、LVEF值、LVEDD指标。结果观察组疗效(95.0%)优于对照组(70.0%),差异具有统计学意义(P <0.05)。两组患者治疗后NT-proBNP均显著降低,LVEF值均显著升高,差异具有统计学意义(P <0.05)。观察组患者的NT-proBNP低于对照组,LVEF高于对照组,差异均具有统计学意义(P <0.05)。结论左西孟旦联合重组人脑利钠肽治疗可显著提高急性心衰疗效,改善患者心功能。
Objective To explore the clinical effect of levosimendan combined with recombinant human brain natriuretic peptide in the treatment of acute heart failure. Methods 40 patients with acute heart failure admitted to the emergency department of internal medicine in our hospital were randomly divided into control group and observation group,20 cases in each group. The control group was treated with levosimendan.The observation group was treated with levosimendan combined with recombinant human brain natriuretic peptide. Before treatment and 72 hours after treatment were selected as observation points. The curative effect, NTproBNP level, LVEF value and LVEDD index were compared between the two groups. Results The curative effect of the observation group(95.0%)was better than that of the control group(70.0%). The difference was statistically significant(P < 0.05). After treatment, NT-proBNP decreased significantly and LVEF increased significantly in both groups(P < 0.05).The NT-proBNP of the observation group was lower than that of the control group, and the LVEF of the observation group was higher than that of the control group(P < 0.05). Conclusion Levosimendan combined with recombinant human brain natriuretic peptide can significantly improve the clinical efficacy and improve cardiac function in patients with acute heart failure.
Objective To explore the clinical effect of levosimendan combined with recombinant human brain natriuretic peptide in the treatment of acute heart failure. Methods 40 patients with acute heart failure admitted to the emergency department of internal medicine in our hospital were randomly divided into control group and observation group,20 cases in each group. The control group was treated with levosimendan.The observation group was treated with levosimendan combined with recombinant human brain natriuretic peptide. Before treatment and 72 hours after treatment were selected as observation points. The curative effect, NTproBNP level, LVEF value and LVEDD index were compared between the two groups. Results The curative effect of the observation group(95.0%)was better than that of the control group(70.0%). The difference was statistically significant(P < 0.05). After treatment, NT-proBNP decreased significantly and LVEF increased significantly in both groups(P < 0.05).The NT-proBNP of the observation group was lower than that of the control group, and the LVEF of the observation group was higher than that of the control group(P < 0.05). Conclusion Levosimendan combined with recombinant human brain natriuretic peptide can significantly improve the clinical efficacy and improve cardiac function in patients with acute heart failure.
引文
[1]曹东来,韩冷,倪杰,等.重组人脑钠肽治疗急性左心衰竭的疗效和安全性研究[J].中国医药,2014,9(12):1741-1743.
[2]中华医学会心血管病学分会,中华心血管病杂志编辑委员会.中国心力衰竭诊断和治疗指南2014[J].中华心血管病杂志,2014,42(2):98-122.
[3]中国医师协会急诊医师分会,中国心胸血管麻醉学会急救与复苏分会.中国急性心力衰竭急诊临床实践指南2017[J].中华急诊医学杂志,2017,26(12):1347-1357.
[4]黄峻.中国心力衰竭流行病学特点和防治策略[J].中华心脏与心律电子杂志,2015,3(2):2-3.
[5]翟莉,李勤明,胡艳丽,等.左西孟旦在急性心衰患者中的临床应用[J].中国分子心脏病学杂志,2017,18(4):2156-2158.
[6]朱丹丹,王晶,贺明轶,等.间歇性使用左西孟旦治疗难治性心力衰竭的临床研究[J].现代药物与临床,2016,31(8):1168-1172.
[7]郑振达,成彩联,曲彩虹,等.重组人脑利钠肽联合左西孟旦治疗急性心肌梗死合并心力衰竭的疗效观察[J].中华老年医学杂志,2015,34(11):1231-1234.
[8]黄燕,胡盛寿.心脏移植术后B型利钠肽/N末端B型利钠肽原升高的临床意义[J].实用器官移植电子杂志,2013,1(3):180-184.
[9]郭牧,张云强,梁海青,等.左西孟旦联合重组人脑利钠肽治疗急性心力衰竭的临床研究[J].临床心血管病杂志,2014,12(4):286-290.
[10]曾晓铧,王静,谭洁.重组人脑钠肽治疗急性心力衰竭的研究进展[J].医学综述,2015,21(1):61-63.
[11]郭牧,张云强,梁海清,等.左西孟旦联合重组人脑利钠肽治疗急性心力衰竭的临床研究[J].临床心血管病杂志,2014,30(4):286-290.
[12]曹俊雄,朱志军,吴丹宁.冻干重组人脑利钠肽联合左西孟旦治疗急性心力衰竭的临床观察[J].中国药房,2016,27(8):1091-1093.
[13]王冬,王岩.左西孟旦及重组人脑利钠肽联合治疗急性心肌梗死合并心功能不全患者的临床观察[J].中国药物经济学,2015,10(z2):101-102.
[14]黄伟胜,罗森华.NT-proBNP对老年慢性心力衰竭患者再住院率及生存率的影响[J].中西医结合心脑血管病杂志,2015,13(2):216-218.
[15]王文龙.左西孟旦与重组人脑利钠肽联合应用治疗急性心衰的疗效观察[J].河北医学,2016,22(9):1535-1536.
[2]中华医学会心血管病学分会,中华心血管病杂志编辑委员会.中国心力衰竭诊断和治疗指南2014[J].中华心血管病杂志,2014,42(2):98-122.
[3]中国医师协会急诊医师分会,中国心胸血管麻醉学会急救与复苏分会.中国急性心力衰竭急诊临床实践指南2017[J].中华急诊医学杂志,2017,26(12):1347-1357.
[4]黄峻.中国心力衰竭流行病学特点和防治策略[J].中华心脏与心律电子杂志,2015,3(2):2-3.
[5]翟莉,李勤明,胡艳丽,等.左西孟旦在急性心衰患者中的临床应用[J].中国分子心脏病学杂志,2017,18(4):2156-2158.
[6]朱丹丹,王晶,贺明轶,等.间歇性使用左西孟旦治疗难治性心力衰竭的临床研究[J].现代药物与临床,2016,31(8):1168-1172.
[7]郑振达,成彩联,曲彩虹,等.重组人脑利钠肽联合左西孟旦治疗急性心肌梗死合并心力衰竭的疗效观察[J].中华老年医学杂志,2015,34(11):1231-1234.
[8]黄燕,胡盛寿.心脏移植术后B型利钠肽/N末端B型利钠肽原升高的临床意义[J].实用器官移植电子杂志,2013,1(3):180-184.
[9]郭牧,张云强,梁海青,等.左西孟旦联合重组人脑利钠肽治疗急性心力衰竭的临床研究[J].临床心血管病杂志,2014,12(4):286-290.
[10]曾晓铧,王静,谭洁.重组人脑钠肽治疗急性心力衰竭的研究进展[J].医学综述,2015,21(1):61-63.
[11]郭牧,张云强,梁海清,等.左西孟旦联合重组人脑利钠肽治疗急性心力衰竭的临床研究[J].临床心血管病杂志,2014,30(4):286-290.
[12]曹俊雄,朱志军,吴丹宁.冻干重组人脑利钠肽联合左西孟旦治疗急性心力衰竭的临床观察[J].中国药房,2016,27(8):1091-1093.
[13]王冬,王岩.左西孟旦及重组人脑利钠肽联合治疗急性心肌梗死合并心功能不全患者的临床观察[J].中国药物经济学,2015,10(z2):101-102.
[14]黄伟胜,罗森华.NT-proBNP对老年慢性心力衰竭患者再住院率及生存率的影响[J].中西医结合心脑血管病杂志,2015,13(2):216-218.
[15]王文龙.左西孟旦与重组人脑利钠肽联合应用治疗急性心衰的疗效观察[J].河北医学,2016,22(9):1535-1536.